Kyowa Kirin secures FDA approval for Crysvita dosing update

The recombinant, fully human monoclonal IgG1 antibody targets fibroblast growth factor 23 in XLH. Credit: Michele Ursi / Shutterstock.com.



  • Kyowa Kirin FDA approval